Treats relapsing forms of multiple sclerosis (MS). ANDA 209638, held by Aurobindo Pharma. Teriflunomide.
As of Nov 16, 2026, ANDA 209638 (Teriflunomide), held by Aurobindo Pharma, was first approved by FDA on Oct 26, 2018, with 9 approved supplements and 0 published complete response letters.
Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2018 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Dec 26, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 26, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 16, 2023 | Supplement 7Manufacturing · Standard review | Approved | None posted |
| Nov 2, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 2, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 7, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 23, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 26, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters